Pegcetacoplan: 52-Week Kidney Benefit Data
- New research indicates that pegcetacoplan, a targeted C3 inhibitor, provides lasting and significant benefits for individuals suffering from C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The...
- The VALIANT trial, a phase 3 study, involved 124 patients.
- Fadi Fakhouri, MD, from Lausanne University Hospital, noted the sustained benefits of pegcetacoplan.
Pegcetacoplan delivers sustained kidney benefits, according to the latest 52-week data from the VALIANT trial. This targeted C3 inhibitor demonstrated meaningful reductions in proteinuria for patients with C3 glomerulopathy adn IC-MPGN. The clinical trial, which included 124 patients, showed that those initially on pegcetacoplan maintained a ample reduction in proteinuria through week 52. Furthermore, patients previously on a placebo experienced similar improvements after switching to the drug. High adherence and good tolerability were also observed. experts like Dr. Fadi Fakhouri highlight the drug’s lasting impact on kidney function, emphasizing the potential to reduce the risk of kidney failure. News Directory 3 provides timely updates on these critical advancements.Discover what’s next for pegcetacoplan and its role in treating these challenging kidney diseases.
Pegcetacoplan Shows Promise in Treating C3 Glomerulopathy and IC-MPGN
New research indicates that pegcetacoplan, a targeted C3 inhibitor, provides lasting and significant benefits for individuals suffering from C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The findings stem from 52-week results of the VALIANT trial, presented at the 62nd european Renal Association (ERA) Congress 2025.
The VALIANT trial, a phase 3 study, involved 124 patients. Participants were administered either pegcetacoplan or a placebo. after 26 weeks, the placebo group transitioned to pegcetacoplan. Key results highlighted a considerable reduction in proteinuria, as measured by the urine protein-to-creatinine ratio (uPCR). Patients initially on pegcetacoplan maintained this reduction through week 52.Those who switched from placebo also experienced similar improvements.
Fadi Fakhouri, MD, from Lausanne University Hospital, noted the sustained benefits of pegcetacoplan. The study revealed that the drug was generally well-tolerated, with high adherence rates among patients.
Specifically, at week 52, the group initially on pegcetacoplan maintained a significant reduction in proteinuria, with a mean uPCR change of -68.3%. The group that switched from placebo to pegcetacoplan experienced a -51.3% reduction at week 52.
Subanalyses also examined patients with nephrotic range proteinuria and those receiving immunosuppressive therapies. David Kavanagh, MD, of the National Renal Complement Therapeutics Center, presented data showing that pegcetacoplan reduced proteinuria in both groups. He emphasized that a 50% reduction in proteinuria could lower the risk of kidney failure.
“the open-label period results confirm pegcetacoplan’s significant effect on kidney function,” Fakhouri said.
What’s next
Further research will explore the long-term effects of pegcetacoplan on kidney function and overall patient outcomes. These studies aim to solidify the role of pegcetacoplan in managing C3 glomerulopathy and IC-MPGN.